JBC Oz Biosciences

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M111902200 on February 26, 2002

J. Biol. Chem., Vol. 277, Issue 20, 17406-17414, May 17, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
277/20/17406    most recent
M111902200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yang, L.-T.
Right arrow Articles by Sap, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yang, L.-T.
Right arrow Articles by Sap, J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

c-SRC Mediates Neurite Outgrowth through Recruitment of Crk to the Scaffolding Protein Sin/Efs without Altering the Kinetics of ERK Activation*,

Liang-Tung YangDagger , Konstantina Alexandropoulos§, and Jan SapDagger

From the Dagger  Department of Pharmacology, New York University School of Medicine, New York, New York 10016 and § Department of Pharmacology, College of Physicians and Surgeons, Columbia University, New York, New York 10032

Received for publication, December 13, 2001, and in revised form, February 20, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

SRC family kinases have been consistently and recurrently implicated in neurite extension events, yet the mechanism underlying their neuritogenic role has remained elusive. We report that epidermal growth factor (EGF) can be converted from a non-neuritogenic into a neuritogenic factor through moderate activation of endogenous SRC by receptor-protein-tyrosine phosphatase alpha  (a physiological SRC activator). We show that such a qualitative change in the response to EGF is not accompanied by changes in the extent or kinetics of ERK induction in response to this factor. Instead, the pathway involved relies on increased tyrosine phosphorylation of, and recruitment of Crk to, the SRC substrate Sin/Efs. The latter is a scaffolding protein structurally similar to the SRC substrate Cas, tyrosine phosphorylation of which is critical for migration in fibroblasts and epithelial cells. Expression of a dominant negative version of Sin interfered with receptor-protein-tyrosine phosphatase alpha /EGF- as well as fibroblast growth factor-induced neurite outgrowth. These observations uncouple neuritogenic signaling in PC12 cells from sustained activation of ERK kinases and for the first time identify an effector of SRC function in neurite extension.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Most analyses that use reductionist systems such as PC12 cells to identify pathways governing neuronal process formation have focused on the Ras/ERK1 pathway, the requirement of which is well established. The neuritogenic effect of constitutively active MEK has been taken to indicate that ERK activation is also sufficient for neuritogenesis. Yet, physiological ERK activation, e.g. in response to EGF, often does not engender neurite extension. An attempt to resolve this paradox has been the postulate that the kinetic pattern of ERK signaling after a stimulus is what dictates the nature of the ensuing response (1). In this view, "sustained" activation of ERK (hours), such as typically seen for FGF or NGF, would be the signal that specifies a neuritogenic outcome as opposed to the "transient" (<1 h) ERK induction associated with non-neuritogenic factors such as EGF. However, such a correlation does not necessarily imply sufficiency or necessity.

Diverse and independent approaches have exposed the necessity of postulating pathways to process formation other than ERK. Recurrently, tyrosine kinases of the SRC family (SFKs) have been proposed as candidates for such "parallel pathways." A mutation in Trk retains ERK induction but abolishes neurite outgrowth by NGF (2). Analysis of platelet-derived growth factor receptor mutants showed that sustained ERK activation per se is insufficient but that neuritogenesis requires additional signals possibly involving SRC (3). v-SRC induces neurite outgrowth in PC12 cells (4), whereas c-SRC inhibition can block outgrowth (5, 6). This crucial role of SFKs in neurite extension is not restricted to PC12 cells but is equally clearly encountered in conditionally immortalized (7) and primary neurons (8, 9). SFKs associate with adhesion molecules that facilitate process elongation (10, 11) and are enriched in nerve growth cones, where they interact with the cytoskeleton in a protein-tyrosine phosphatase (PTP)-dependent manner (12).

In fibroblasts and epithelial cells, SRC is intimately implicated in phosphorylation of focal adhesion proteins, turnover of these structures, and cell motility (13, 14). v-SRC can activate or inhibit ERK kinases, depending on the cell type and stage of transformation (15, 16). Its action as a transforming oncogene can be separated from its ability to activate Ras and ERK (17, 18). One of the major SRC substrates, Cas, in complex with the adaptor Crk, is a key mediator of cell migration in fibroblasts and epithelial cells (19-23). By contrast, in neuronal cells, the identity of signaling steps downstream of c-SRC has remained obscure. One reason for this lack of progress has been the previous extensive reliance on mutationally activated v-SRC. Given the drastic degree of kinase activation and deregulation of the latter, this approach has not been informative regarding the function of endogenous c-SRC. Indeed, the signaling pathways downstream of oncogenic and cellular SRC proteins were recently shown to differ substantially; for instance, c-SRC-mediated activation of certain promoters relies exclusively on Rap1, whereas transforming SRC alleles also signal through Ras (24). Approaches using oncogenic SRC alleles are particularly compromised by the experimental difficulty of separating the biological effect of mutationally activated v-SRC from its ability to deregulate ERK kinases (15, 16).

SFKs are regulated by a conformational mechanism that is controlled by phosphorylation. Intramolecular interactions between the SH2 domain and a C-terminal tyrosine phosphorylation site (Tyr-527 in chicken SRC) in combination with SH3-mediated interactions stabilize a kinase-inactive conformation (25). In consequence, wild type SRC family kinases are reversibly activated in situ by ligands to their SH2 and SH3 domains (24, 26, 27) or by PTPs that mediate Tyr(P)-527 dephosphorylation (28). Extensive evidence identifies receptor-PTPalpha (RPTPalpha ) as one such physiological Tyr(P)-527 phosphatase. This PTP, which is particularly abundant in neural tissue, associates physically with SRC and Fyn (26, 29, 30), and its overexpression activates these kinases (26, 29-32); conversely, loss of RPTPalpha leads to dose-dependent reductions in SRC and Fyn kinase activities and generates integrin signaling deficits similar to SRC-/- cells (33, 34). RPTPalpha itself undergoes tyrosine phosphorylation at a residue (Tyr-798) in its C terminus. This modification leads to Grb2 recruitment (35, 36) and alters RPTPalpha function (36), SRC-activating ability (26), and localization (37). In the present study, we have exploited the role of RPTPalpha as a physiological SRC activator to identify signaling events downstream of SRC in neuronal cells.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Cell Culture-- PC12 cells were cultured in Dulbecco's modified Eagle's medium plus 10% fetal calf serum and 10% horse serum. Retrovirus production and infection were as described (36). For neuritogenesis, 5 × 104 cells were seeded per 35-mm plate, grown overnight, and starved (0.5% fetal calf serum plus 0.5% horse serum) for 16-20 h. To this medium was then added 50 ng/ml acidic FGF plus 5 µg/ml heparin or 100 ng/ml EGF.

Data Analysis-- After 2 days of stimulation, neurite length was measured on photographed fields containing 100-250 cells. Data were expressed in two ways; first, as total neurite length averaged over cell number (bar diagrams; y axis = cell diameters); second, as percent neurite-bearing cells (percent cells bearing at least one neurite larger than two cell diameters). The level of statistical significance was assessed by a two-sided t test (unequal variance). In bar diagrams, error bars always indicate 95% confidence intervals. For numerical data (% neurite-bearing cells), the extent of a 95% confidence interval is indicated by the number between brackets. All key conclusions were re-confirmed on independent clones and/or pools of clones selected en masse.

Antibodies and Plasmids-- Anti-RPTPalpha (36), and anti-Sin (38) sera have been described. Anti-SRC was from Calbiochem. For the immunoprecipitation/in vitro ERK assay and immunoblotting, anti-ERK-1 C-16 and anti-ERK2 C-14 (Santa Cruz) were used, respectively; anti-phospho-ERK antibody was from New England Biolabs. Anti-phosphotyrosine antibody 72 was described (36); 4G10 was from Upstate Biotechnology. Anti-Cas was a gift of T. Parsons and A. Bouton (University of Virginia). Anti-CrkL C-20 was from Santa Cruz. Anti-Nck sera were provided by E. Skolnik (New York University) or from Santa Cruz (C-19).

RPTPalpha constructs were described (36). The Sin deletion SinSD, lacking residues 101-256 (38), was generated using the Exsite kit (Stratagene). Two retroviral vectors were used: pLXSHD (36), and pBabeI-EG (D. Unutmaz, NYU). The latter encodes an long terminal repeat-driven di-cistronic transcript consisting of the transduced cDNA and green fluorescent protein (3' to an internal ribosomal entry site). cDNA inserts were ligated between XhoI and BamHI of pLXSHD or into the BamHI site of pBabeI-EG.

Immunoprecipitation and Immunoblotting-- Lysates in 50 mM Hepes, pH 7.5, 1% Triton X-100, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 10% glycerol, 1 mM Na3VO4, 50 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml leupeptin, and 10 µg/ml aprotinin were cleared at 16,000 × g for 15 min, and equal amounts of protein were immunoprecipitated with antibodies conjugated to protein A-Sepharose for 2 h at 4 °C. SDS-PAGE-separated proteins were transferred to nitrocellulose and subjected to immunoblotting followed by ECL or 125I-autoradiography.

Immunofluorescence-- Cells on collagen-coated coverslips were fixed (4% paraformaldehyde/phosphate-buffered saline, 20 min) and permeabilized (0.1% Triton X-100, phosphate-buffered saline, 20 min). They were blocked in phosphate-buffered saline plus 10% fetal calf serum for 30 min and incubated with primary antibody for 1 h followed by 10 µg/ml secondary antibody and examined under a Zeiss photomicroscope.

In Vitro Kinase Assays-- For SRC assays, cells were lysed in radioimmune precipitation buffer (50 mM Hepes, pH 7.4, 1% deoxycholic acid, 1% Triton X-100, 0.1% SDS, 150 mM NaCl, 1 mM EGTA) plus protease and PTP inhibitors. Anti-SRC precipitates were washed 3× in radioimmune precipitation buffer and twice in TBS (150 mM NaCl, 20 mM Tris, pH 7.5) and split for anti-SRC immunoblotting and kinase assay. Enolase substrate was denatured in 50 mM sodium acetate at 30 °C for 5 min and neutralized with 1 M Tris-HCl, pH 7.5. Reactions (50 µl) in kinase buffer (20 mM Tris, pH 7.5, 5 mM MnCl2) contained 12.5 µg of enolase plus 10 µCi of [gamma -32P]ATP and were incubated at 30 °C for 10 min.

ERK1 assays involved precipitation from Triton lysate and incubation in 25 µl of buffer (10 mM Tris, pH 7.3, 10 mM MgCl2) with 10 µCi of [gamma -32P]ATP plus 12.5 µg of myelin basic protein for 25 min at 30 °C. Reactions were stopped by SDS-PAGE sample buffer, and gel autoradiographs were quantitated using phosphorimaging.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

EGF Induces Neurite Outgrowth in c-SRC-overexpressing PC12 Cells-- v-SRC induces growth factor-independent neuritogenesis in PC12 cells (4), but how this may relate to the physiological function of c-SRC is poorly understood. We used retroviral infection to generate a pool of PC12 cells overexpressing c-SRC (Fig. 1A). This conferred upon EGF (normally a solely mitogenic factor (1)) an ability to induce neurite formation equal to that of a bona fide neuritogenic factor (FGF) in control cells (Fig. 1C). This suggests that an SRC-dependent function can contribute to converting a non-neuritogenic factor (EGF) into a neuritogenic one. Increases in tyrosine phosphorylation after c-SRC overexpression were largely limited to four proteins of 130, 90, 70, and 60 kDa (the latter being SRC itself) (Fig. 1B).


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 1.   SRC expression allows neurite outgrowth in response to EGF. PC12 cells were infected with an SRC-encoding or control retrovirus, and lysates were analyzed by anti-SRC (A) or anti-phosphotyrosine (B) immunoblotting (IB). C, neurite formation in the absence or presence of EGF or FGF. Data are expressed as averaged neurite length/cell (bar diagram; y axis = cell diameters) or as % neurite-bearing cells (% n, numbers below diagram = % of cells bearing a neurite larger than two cell diameters). 95% confidence intervals are indicated by error bars (in the bar diagram indicating neurite lengths) or by the numbers between brackets (next to numbers below indicating % neurite bearing cells). Statistical significance is tested with respect to unstimulated control PC12 cells or to unstimulated c-SRC expressing cells (*, p < 0.05; **, p < 0.01; ***, p < 0.001).

RPTPalpha Localizes to Cell-Cell Contact Zones and Tips of Spontaneous Spikes and Activates Endogenous SRC-- To ask whether endogenous levels of c-SRC could similarly contribute to conversion of EGF into a neuritogenic factor, we relied on the known c-SRC-activating function of RPTPalpha (26, 29, 31-34). We previously reported generation of PC12 lines expressing wt or mutant RPTPalpha (36). The mutants used were RPTPalpha CCSS, catalytically inactive due to mutation of the active site cysteine residues in either PTP domain (Cys-442, Cys-732) to serine, and RPTPalpha Y798F, in which Tyr-798, the site of tyrosine phosphorylation in RPTPalpha , was mutated to phenylalanine (resulting in loss of Grb2 recruitment but normal in vitro catalytic activity (35)). Immunofluorescence revealed RPTPalpha was membrane-localized and concentrated in cell-cell contact zones and at the tips of spontaneous spikes (Fig. 2A); no significant differences were seen in localization of wt versus mutant proteins (not shown).


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 2.   Activation of endogenous SRC after expression of wt RPTPalpha and RPTPalpha Y798F in PC12 cells. A, intracellular localization of RPTPalpha by immunostaining. The arrows point to localization at ends of spontaneous extensions. B, SRC kinase assay. Lysates were subjected to anti-SRC immunoprecipitation (IP), and precipitates were split in two. One-half was subjected to in vitro SRC kinase assay using enolase as exogenous substrate (top); the other half was analyzed by anti-SRC immunoblotting (IB).

wt RPTPalpha and RPTPalpha Y798F, but not RPTPalpha CCSS, moderately increased c-SRC activity (by 2-fold), with the level of c-SRC protein remaining unchanged (Fig. 2B). This increase in specific activity likely reflects the well documented ability of RPTPalpha to reduce the phosphorylation level of the Tyr-527 residue in c-SRC (33, 34). Contrasting with the situation for c-SRC-overexpressing cells, we observed no constitutive effects of RPTPalpha on cell morphology or on neurite extension in the absence of added growth factors (data not shown and Fig. 3B).


View larger version (73K):
[in this window]
[in a new window]
 
Fig. 3.   RPTPalpha causes SRC- and MEK-dependent neurite outgrowth in response to EGF, and this effect is potentiated by mutation of the Tyr-798 phosphorylation site in RPTPalpha . PC12 clones (control or expressing wt RPTPalpha , RPTPalpha CCSS (catalytically inactive), or RPTPalpha Y798F (lacking the Tyr-798 phosphorylation site in RPTPalpha )) were exposed to EGF or FGF for 48 h in the absence or presence of the MEK inhibitor PD98059 (10 µM) or the SRC inhibitor PP1 (1 µM). The inhibitory effects of wt RPTPalpha and stimulatory effect of RPTPalpha Y798F on FGF-induced neuritogenesis were described previously (36) and are included here as controls. A, neurite outgrowth data measured over 100-250 cells. Data and 95% confidence intervals are expressed as described under "Materials and Methods" and in the legend of Fig. 1 (histogram = average neurite length; numbers = fraction of neurite-bearing cells). The level of statistical significance was determined by a two-sided t test with respect to stimulated vector (V; control) cells (i.e. left bar in each graph) (*, p < 0.05; ***, p < 0.001). B, photographs of representative fields after EGF treatment in the absence or presence of the indicated inhibitors.

RPTPalpha Stimulates EGF-induced Neurite Outgrowth in a Manner That Requires Both SRC and ERK-- As reported previously (36), the presence of wt RPTPalpha , but not catalytically inactive RPTPalpha CCSS, impairs the ability of FGF (and NGF; data not shown) to cause neurite outgrowth. Mutation of the Tyr-798 phosphorylation site in RPTPalpha not only abolishes, but inverts this effect of wt RPTPalpha , since RPTPalpha Y798F behaves instead as a net potentiator of FGF-induced outgrowth (36) (Fig. 3A, right panel).

We here report that, unexpectedly, the effect of wt RPTPalpha on responsiveness to EGF was the opposite of that on FGF responsiveness; that is, wt RPTPalpha converted EGF into a promoter of neurite outgrowth (Fig. 3A, left panel). Furthermore, RPTPalpha Y798F promoted neurite outgrowth in response to EGF even more powerfully than wt RPTPalpha (Fig. 3A, left panel). In contrast, RPTPalpha CCSS did not potentiate EGF responsiveness; this catalytically inactive protein even somewhat reduced the formation of short spikes that occurs in response to EGF. It is conceivable that this weak inhibitory effect of RPTPalpha CCSS reflects dominant negative-like interference with the function of endogenous RPTPalpha or of a related RPTP. However, to what extent C-to-S mutant PTPs can indeed be relied on to be specific and true dominant-negatives is as yet still unclear; hence, interpretation of the significance of this observation is probably premature. Assessment of mRNA levels by Northern blotting for the metalloprotease transin, a late marker for NGF-induced neuronal differentiation of PC12 cells (39, 40), revealed that the EGF-induced neurite extension correlated fully with expression of this marker. EGF treatment lead to transin induction in cells expressing wt RPTPalpha or RPTPalpha Y798F but not RPTPalpha CCSS; moreover, this effect was stronger in RPTPalpha Y798F than in wt RPTPalpha -expressing cells (supplemental data included in the on-line version of manuscript). This indicates that EGF induced not merely morphological effects but also changes in gene expression.

The ability of RPTPalpha to confer outgrowth-promoting activity on the previously non-neuritogenic EGF is reminiscent of c-SRC overexpression, although less drastic, since the effect of RPTPalpha remained fully EGF-dependent (Fig. 1C versus Fig. 3, A and B, and data not shown). Pharmacological SRC inhibition using PP1 abolished the neuritogenic effect of RPTPalpha and RPTPYalpha 798F on stimulation with EGF, whereas cell morphology and viability remained unaffected (Fig. 3B), indicating that the stimulatory effect of RPTPalpha on EGF-induced neuritogenesis depends on the activity of a SFK. At the same time, EGF-induced neurite outgrowth still continued to be dependent on ERK activity, as shown by application of PD98059 (a selective MEK1 inhibitor) (Fig. 3B). We did observe a tendency of EGF-stimulated RPTPalpha Y798F-expressing cells to still form "stumps" in the presence of 10 µM PD98059. However, <2% of cells formed protrusions longer than 2 cell diameters, and any protrusions formed were <1 cell diameter. The number of these protrusions could be reduced significantly by raising the concentration of PD98059 to 25 µM (data not shown). Hence, these protrusions cannot be referred to as neurites, and their true biological significance is questionable at best.

Conversion of EGF into an Outgrowth-promoting Factor by RPTPalpha Is Not Accompanied by Alteration in ERK Kinetics-- A widely cited model traces back the divergent effects of EGF versus FGF on normal PC12 cells to differences in their kinetics of ERK activation. It has been proposed that the relatively transient ERK activation induced by EGF is insufficient for neuritogenesis, which would require the more sustained (>2 h) activation of ERK that is observed for NGF or FGF. This hypothesis was prompted by observations that experimental induction of neurite formation by overexpression of many signaling molecules is invariably accompanied by a shift in ERK activation kinetics from a transient to a sustained mode (1). Hence, we wished to determine whether the ability of wt RPTPalpha and RPTPalpha Y798F to convert EGF into a neuritogenic factor could similarly be accounted for by an alteration, from transient to sustained, in the kinetics of EGF-induced ERK activation.

We observed that wt RPTPalpha inhibited ERK activation in response to FGF at both the 5-min and 6-h time points, with wt RPTPalpha more potent at reducing ERK activation than RPTPalpha CCSS and RPTPalpha Y798F (Fig. 4A), suggesting that optimal inhibition required both catalytic activity and Grb2 binding. Although reduced ERK activation might explain the ability of wt RPTPalpha to inhibit FGF-induced neurite formation (Fig. 3A), this correlation broke down for RPTPalpha Y798F, which reduced ERK activation by FGF (Fig. 4A and data not shown) but enhanced neurite extension induced by this factor (Fig. 3A).


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 4.   RPTPalpha decreases ERK activation in response to acidic FGF but does not affect the extent and kinetics of ERK activation in response to EGF. A and B, relative ERK activity at various time points as determined by in vitro ERK kinase assay. A representative autoradiograph is shown in A. ERK activities in response to FGF relative to the vector control were 0.4 (wt), 0.5 (CCSS), and 0.6 (YF) at 5 min and 0.4 (wt), 0.6 (CCSS), and 0.6 (YF) at 6 h. Quantitation and statistical analysis of 3 independent experiments is shown in B. Error bars denote 95% confidence intervals. Statistical significance was tested by a two-sided t test with respect to EGF-stimulated empty vector-infected (control) cells (i.e. left column in each graph) (*, p < 0.05). C, lysates from clones exposed to EGF for the indicated times were analyzed by immunoblotting with an antibody against activated (phosphorylated) ERK1/2. For each time point, vector-infected (V, control) cells were also stimulated with acidic FGF as a positive control. MBP, myelin basic protein.

The situation in the case of EGF was analyzed in extensive detail. As expected from the literature (1), in control cells, EGF- and FGF-induced ERK activities were comparable at the 5-min time point but differed significantly at later time points, with FGF-induced activation sustained longer (Fig. 4, A-C). Strikingly, however, neither wt RPTPalpha nor RPTPalpha Y798F (which both potentiate EGF-induced neurite outgrowth; see Fig. 3) potentiated the extent of ERK induction by EGF. In the short term (5 min), expression of wt or mutant RPTPalpha actually tended to reduce ERK activation (Fig. 4B, left panel). More importantly, none of the wt or mutant RPTPalpha proteins significantly altered EGF-induced ERK activation at the late time point (6 h) (Fig. 4B, right panel). As expected from the literature (1), in the control (vector) cells at late time points, EGF-induced ERK activation was significantly lower than FGF-induced activation (Fig. 4B, right panel, and C). Similar conclusions regarding the effect of RPTPalpha on ERK activation were reached by in vitro kinase assay (Fig. 4B) and by immunoblotting with phospho-specific antibodies for the activated state of ERK 1 and 2 (Fig. 4C).

We conclude that wt RPTPalpha and RPTPalpha Y798F counteract the induction of ERK by FGF but do not alter the extent or kinetics of ERK activation in response to EGF. This breakdown of the correlation between neurite outgrowth and the extent of sustained ERK induction leaves the ability of wt RPTPalpha and RPTPalpha Y798F to induce a neuritogenic response to EGF unexplained.

RPTPalpha in a SRC-dependent Manner Elevates Tyrosine Phosphorylation of the Docking Proteins Cas and Sin-- In a search for alternative explanations for conversion of EGF into an outgrowth-promoting factor, we assessed how RPTPalpha affected cellular tyrosine phosphorylation. We found that wt RPTPalpha and RPTPalpha Y798F (but not RPTPalpha CCSS) specifically elevated tyrosine phosphorylation of a 90-kDa protein and also caused a more modest increase in a 130-kDa species (Fig. 5A). This pattern is similar to that observed after an increase in c-SRC expression (Fig. 1B). EGF or FGF did not affect the phosphotyrosine content of these 90- and 130-kDa proteins, and wt or mutant RPTPalpha did not alter the overall patterns of tyrosine phosphorylation induced in response to EGF or FGF (not shown).


View larger version (50K):
[in this window]
[in a new window]
 
Fig. 5.   RPTPalpha elevates tyrosine phosphorylation of Sin and Cas in a SRC-dependent manner and enhances complex formation with Crk and Nck. A, equal amounts of lysate from clones infected with control, wt, or mutant RPTPalpha -expressing virus were analyzed by anti-phosphotyrosine (P-Tyr) immunoblotting. Proteins migrating at 130 and 90 kDa are indicated. B, equal amounts of total lysate from vector-infected (V) or RTPTalpha -expressing cells (Wt) were subjected to anti-Sin (left panels) or anti-Cas (right panels) immunoprecipitation. In lanes marked IP, the immune precipitates were split into two portions. One portion was immunoblotted with anti-phosphotyrosine (upper panels), and the other was immunoblotted with anti-Sin (lower panel, left) or anti-Cas (lower panel, right). In lanes marked SUP, aliquots of lysates collected before (bfIP) or after immunoprecipitation (afIP) with the respective antibodies were analyzed by immunoblotting with the antibodies indicated on the left. C, lysates were subjected to immunoprecipitation with anti-CrkL or anti-Nck, and immune precipitates were analyzed by immunoblotting with anti-Cas, -Sin, -CrkL, and -Nck. D, anti-Sin immune precipitates were prepared from control cells (V) or cells expressing wt RPTPalpha (WT) or RPTPalpha Y798F (YF) treated or not with the SRC inhibitor PP1 (1 µM) for 30 min before lysis. Precipitates were analyzed by anti-phosphotyrosine (top) or anti-Sin (bottom) immunoblotting. E, anti-CrkL precipitates were prepared from control cells (V) or cells expressing wt RPTPalpha (WT) treated or not with the SRC inhibitor PP1 (1 µM) for 30 min before lysis. Precipitates were analyzed by immunoblotting with anti-Sin (top), anti-Cas (middle), and anti-CrkL (bottom).

In trying to characterize these proteins, we found (data not shown) that RPTPalpha had not affected phosphorylation of cortactin and Cbl (both SRC substrates) or of FRS-2 (implicated in FGF-dependent PC12 differentiation). However, we successfully identified the proteins whose tyrosine phosphorylation level was elevated by RPTPalpha as Sin (90 kDa) and Cas (130 kDa) (Fig. 5, B and D), 2 related docking proteins and known SRC substrates (21, 22). Quantitative immunodepletion experiments demonstrated that these 2 proteins (or associated proteins of similar sizes) accounted for the bulk of the RPTPalpha -induced increase in tyrosine phosphorylation at 90 and 130 kDa (Fig. 5B).

Pharmacological SRC inhibition was used to determine whether the RPTPalpha -induced increase in tyrosine phosphorylation of Sin required SRC activity. As shown in Fig. 5D, the SRC inhibitor PP1, along with its ability to inhibit neurite outgrowth described above (Fig. 3B), also reduced tyrosine phosphorylation of Sin to undetectable levels, indicating that RPTPalpha -induced phosphorylation of Sin is fully SRC-dependent.

RPTPalpha Induces Complex Formation of Sin and Cas with the Adaptors Crk and Nck-- In fibroblasts, Cas associates with, and is a substrate, an effector, and an activator of c-SRC (22), controlling organization of the actin cytoskeleton, cell migration, and activation of JNK kinases (21, 41, 42). Sin (Efs), whose expression is more restricted than Cas, was isolated in independent screens as a ligand for the SH3 domains of both SRC (38) and Fyn (43). A third mammalian member of this family, HEF-1, was isolated on the basis of its ability to induce pseudohyphal growth in yeast (21). All three share a common domain structure consisting of an SH3 domain, a "substrate" domain containing tyrosine phosphorylated SH2 binding sites, a proline-rich region, and a C-terminal domain with SH3 and SH2 consensus binding sites for SFKs (Fig. 6A) (21). Their association with cytoplasmic tyrosine kinases is followed by phosphorylation of the substrate region and ensuing recruitment of adaptors and other signaling proteins, leading to assembly of higher order complexes with the potential for interactions between associated effectors (21). RPTPalpha enhanced such recruitment of the adaptor CrkL to Sin and Cas, as shown by analysis of anti-CrkL immune precipitations from control and wt RPTPalpha -expressing cells by anti-Cas or anti-Sin immunoblotting (Fig. 5C). Similar results were obtained for CrkII (which is less abundant in PC12 cells than CrkL (44); not shown) and for Nck (Fig. 5C). Consistent with the ability of the SRC inhibitor PP1 to antagonize the increase in tyrosine phosphorylation of Sin that is induced by RPTPalpha (Fig. 5D), PP1 also reversed the increase in RPTPalpha -induced complex formation between Sin or Cas and CrkL (Fig. 5E).


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 6.   RPTPalpha /SRC-dependent neurite extension requires tyrosine phosphorylation of Sin and Crk. A, schematic diagram of the Cas, Sin, and SinSD proteins. SR, substrate region containing phosphorylatable tyrosines that constitute binding sites for adaptors; PL, proline-rich SRC-SH3 binding sites; Y, tyrosine motif constituting a SRC-SH2 binding site; C, C-terminal region of homology between Cas and Sin (21). B, expression of SinSD interferes with tyrosine phosphorylation of endogenous Sin. Parental cells and cells expressing wt RPTPalpha or RPTPalpha Y798F were infected with control (vector (V)) or SinSD-expressing virus. Total lysates (TL) were analyzed by immunoblotting (IB) with anti-RPTPalpha (upper) and with anti-Sin (second panel from top). Anti-Sin immune precipitates (IP) were analyzed by immunoblotting with anti-phosphotyrosine (third panel from top) and with anti-Sin (bottom panel). C, SinSD blocks neuritogenesis of RPTPalpha -expressing cells in response to EGF. Pools of cells expressing wt RPTPalpha or RPTPalpha Y798F in the absence of presence of SinSD were exposed to EGF, and average neurite length (expressed in cell diameters) was measured after 48 h. Error bars denote 95% confidence intervals; Statistical significance for SinSD-infected RPTPalpha (WT) and SinSD-infected RPTPalpha (YF) cells was tested with respect to vector-infected RPTPalpha (WT) cells and vector-infected RPTPalpha (YF) cells, respectively (***, p < 0.001). D, FGF-induced neurite outgrowth in parental PC12 cells (Uninf.) or cells infected with control empty vector or a SinSD-expressing retrovirus. E, schematic representation of dominant-negative CrkR38K, in which a lysine residue critical for SH2 domain function was mutated to arginine. F, expression of CrkR38K. Pools of cells expressing wt RPTPalpha (WT) or RPTPalpha Y798F (YF) were infected with empty (vector (V)) or CrkIIR38K-encoding retrovirus, and expression of RPTPalpha and CrkIIR38K was monitored by immunoblotting. G, CrkR38K blocks neuritogenesis of RPTPalpha -expressing cells in response to EGF. Cells expressing wt RPTPalpha (left) or RPTPalpha Y798F (right) in the presence or absence of CrkIIR38K were exposed to EGF for 48 h, and average neurite length was measured (**, p < 0.01). Average neurite length in control (non-Crk)-superinfected RPTPalpha -expressing cells was somewhat lower than in Fig. 3 due to reduced RPTPalpha expression as a consequence of superinfection (data not shown).

Sin-Crk Coupling Is a Necessary Mediator of RPTPalpha /SRC-dependent Neuritogenesis-- To test the functional relevance of increased phosphorylation of Sin as caused by RPTPalpha -induced activation of SRC, we designed a mutant, SinSD, which lacks the substrate region that encompasses the tyrosine residues whose phosphorylation recruits Crk and Nck (Fig. 6A). By retaining the binding sites for the SH2 and SH3 domains of SRC and Fyn, we expected SinSD to compete with endogenous Sin for association with SRC and, thus, to antagonize assembly of productive complexes around endogenous Sin. An analogous mutant of Cas has been successful in elucidating the contributions of Cas to cell migration (20) and JNK activation in fibroblasts (42).

Parental PC12 cells and wt RPTPalpha or RPTPalpha Y798F expressors were infected with a control or SinSD-expressing retrovirus. As expected, SinSD successfully and specifically interfered with tyrosine phosphorylation of endogenous Sin (Fig. 6B). No effect of SinSD was noted on the growth rate or morphology or unstimulated cells (not shown). However, SinSD interfered with the neuritogenic response of wt RPTPalpha - and RPTPalpha Y798F-expressing cells to EGF (Fig. 6C) and of parental PC12 cells to FGF (Fig. 6D). This indicates that endogenous Sin is a necessary effector for the ability of RPTPalpha to convert EGF into a neuritogenic factor and that normal endogenous Sin function is necessary for optimal FGF-induced outgrowth. We also observed that Sin overexpression potentiated the RPTPalpha effect on EGF-induced neuritogenesis (Ref. 45; data not shown), further consistent with Sin being a limiting effector downstream from RPTPalpha -activated c-SRC.

A caveat to the above (and many) dominant negative approaches is that SinSD may compete for access to c-SRC, not only with endogenous Sin but also with other SRC substrates. Hence, whereas the result in Fig. 6C actually constitutes powerful additional evidence for the involvement of SRC (or Fyn) in RPTPalpha -induced neurite outgrowth in response to EGF, the effect of SinSD might still merely reflect displacement of another, more critical but unidentified, SRC substrate. To alleviate this concern, we asked whether Crk, as a downstream effector of Sin, would be similarly important for EGF/RPTPalpha -induced neuritogenesis. We introduced a CrkII mutant, CrkR38K, into wt RPTPalpha - or RPTPalpha Y798F-expressing cells (Fig. 6F); this mutant adaptor contains a point mutation in its SH2 domain that abolishes its ability to associate with tyrosine-phosphorylated docking proteins (Fig. 6E). It can be expected to interact with the full range of effectors available to endogenous CrkII but to sequester them in a complex incapable of associating with endogenous docking proteins for Crk such as Cas and Sin. The experiment revealed clear interference of CrkR38K with RPTPalpha /SRC-dependent neurite outgrowth (Fig. 6G).

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Correlative evidence originally gave rise to the hypothesis that the qualitative distinction between a non-neuritogenic versus a neuritogenic response is dictated by quantitative differences in ERK signaling (1). We observed here conversion of a non-neuritogenic (EGF) into a neuritogenic factor without alteration in the extent or kinetics of ERK induction. Moreover, in response to FGF, wt RPTPalpha and RPTPalpha Y798F inhibited ERK activation, yet the latter elicited neurite extension. Our data thus demonstrate that the kinetic pattern of ERK activation does not constitute a necessary determinant of growth factor specificity. Potentially related observations have been made using other approaches, e.g. studying the synergism between NGF and IL-6 in a particular variant PC12 line (46), or studying the effect of stable transfection of GTPase-deficient G protein subunits (47) (however, in the latter case, the effect was constitutive, not showing the growth factor dependence observed here). In the present study, we identify SRC-mediated assembly of Sin-Crk complexes as the "alternative" pathway that contributes to formation of neuritic processes.

The latter conclusion is based on 1) the well established function of RPTPalpha in SRC activation (26, 29, 31-34) (Fig. 2B); 2) the similar effects of c-SRC (Fig. 1C) and RPTPalpha (Fig. 3) on EGF-induced neuritogenesis; 3) the fact that pharmacological SRC inhibition abolished the ability of RPTPalpha to alter the nature of the response to EGF (Fig. 3B); 4) the similarity between the patterns of tyrosine phosphorylation induced by RPTPalpha and c-SRC (Figs. 1B and 5A); 5) the observed SRC-dependent increase in phosphorylation and Crk binding of Sin and Cas, two known c-SRC substrates (Fig. 5B); and 6) the ability of both the dominant-negative SRC substrate SinSD and a dominant-negative version of the associated adaptor CRK to inhibit neuritogenesis (Fig. 6, C and F). Although each argument is by itself subject to alternative interpretations, taken together they strongly implicate the cascade SRC > Sin > Crk as a signaling cassette capable of contributing to neurite outgrowth. Notwithstanding the wealth of previous evidence implicating SRC in neurite formation, the identity of its downstream effectors had remained surprisingly enigmatic; to our knowledge, the present demonstration of the role of Sin-Crk complexes constitutes the first elucidation of the mechanism of action of SFKs in this process. We consistently noted that expression of dominant negative versions of Sin or Crk reduced RPTPalpha /EGF- or FGF-induced neurite outgrowth but did not altogether abolish it (Fig. 6, C, D, and G). Further study will determine whether this reflects an only partial dominant negative effect (for instance because of an inability to achieve insufficient expression levels of SinSD or Crk-R38K) or, more interestingly, reflects the existence and function of alternative effectors (other than Sin) downstream of SRC that function in neurite outgrowth.

Docking of Crk to Cas, a close homolog of Sin, is a crucial signaling step in fibroblast migration, acting in an ERK-independent manner (19-21, 23), and PTPs that dephosphorylate Cas also severely affect cell migration (28). Given the mechanistic analogies between migration and neurite extension, the contribution of related scaffolding proteins and effector pathways to the latter would thus not seem implausible, yet had thus far not been recognized.

The pathway outlined above needs to be qualified in two ways. First, it is unclear to what extent the effects observed occur through activation of SRC versus Fyn. Although RPTPalpha regulates both kinases (30, 33, 34), the role of Fyn in PC12 cells is a totally unexplored issue that may require further study; however, because Sin is a common substrate for both (38, 43), it may constitute a point of convergence. Second, we have not been able to dissect with reasonable certainty the respective contributions of Cas versus Sin. Given their similarity, antibody cross-reaction, common binding partners, and ability to heterodimerize (21, 48), resolution of this issue will have to rely on reagents as yet to be developed, such as cell lines that are null for either.

Strikingly, wt RPTPalpha potentiated the neuritogenic capacities of EGF but inhibited FGF-dependent neuritogenesis (36). The latter function likely results from a separate ability of RPTPalpha to impair FGF-induced ERK activation, which offsets the neuritogenesis-stimulating effect of activating the SRC-Sin-Crk pathway. Two arguments suggest that this inhibitory effect of RPTPalpha on FGF signaling involves a non-SRC substrate for RPTPalpha that is important only for FGF/NGF-mediated outgrowth. First, c-SRC overexpression mimicked the stimulating effect of RPTPalpha on EGF responsiveness but not its inhibitory effect on FGF responsiveness (Fig. 1C versus Fig. 3A). Hence, the effect of RPTPalpha on FGF signaling must diverge from that on EGF responsiveness upstream of SRC. Second, the two functions could be mutationally separated; the ability of RPTPalpha to inhibit FGF-induced outgrowth is dependent on its Tyr-798 phosphorylation site, but its outgrowth-eliciting ability in response to EGF is not. Thus, abolishing the ability of RPTPalpha to be phosphorylated (the Y798F mutation) converts RPTPalpha from an inhibitor to a net stimulator of FGF-induced neurite outgrowth (most likely due to an additive effect of enhanced Sin-Crk signaling) and further potentiates the ability of RPTPalpha to induce neurite outgrowth in response to EGF. We suggest that phosphorylation of Tyr-798 in RPTPalpha is necessary for the ability of RPTPalpha to dephosphorylate a substrate in the pathway from the FGF receptor to ERK activation. Such modulation of the substrate specificity of RPTPalpha by Tyr-798 phosphorylation could occur in various ways, e.g. displacement (as described for the RPTPalpha -Tyr-798/SRC-SH2 interaction in fibroblasts (26); but see below), RPTPalpha -bound Grb2 acting as an adaptor mediating recruitment of a specific substrate to RPTPalpha , or altered RPTPalpha intracellular localization (37).

Zheng et al. (31), and den Hertog et al. (32) reported 3-6-fold and 4-6-fold increases in SRC kinase activity following RPTPalpha overexpression. The comparatively more modest (2-fold; Fig. 2) effect of RPTPalpha on c-SRC activity seen here in PC12 cells may reflect a more modest level of RPTPalpha overexpression in the present case or, alternatively, may be an intrinsic feature of PC12 cells. De-phosphorylation of Tyr-527 activates c-SRC 10-20-fold (49). However, increases of this magnitude in total cellular SRC activity are never observed. Rather, increases in overall cellular SRC activity that are of physiological significance tend to be much more modest, in all probability reflecting activation of only a distinct subpopulation of the total content of cellular SRC. EGF and NGF were reported to increase tyrosine phosphorylation of c-SRC by a few fold (50). Determining to what extent the RPTPalpha -activated and growth factor-activated SRC pools may be related or overlapping should be an area of detailed and careful further analysis.

Although mutation of Tyr-798 abolished the ability of RPTPalpha to inhibit FGF-dependent outgrowth, we observed it to have only minor effects on the ability of RPTPalpha to activate SRC. Thus, wt RPTPalpha and RPTPalpha Y798F both enhanced in vitro SRC kinase activity (Fig. 2B), in vivo phosphorylation of the SRC substrate Sin (Fig. 5), and EGF-dependent neurite outgrowth itself (Fig. 3). We have tried to quantitate the effect of the Y798F mutation precisely enough so as to be able to document small effects of it on SRC activation or on tyrosine phosphorylation of Sin. These experiments (not shown) suggested that the slightly lower SRC activation by RPTPalpha Y798F as compared with wt RPTPalpha (Figs. 2B, and 5A) in part reflects the somewhat lower level of expression of the RPTPalpha Y798F mutant protein. Our data differ from those of Zheng et al. (26), who observed that SRC activation by RPTPalpha in fibroblasts is highly dependent on the Tyr-798 phosphorylation site in RPTPalpha (to displace the Tyr-527 substrate site from the SRC SH2 domain) (26). Possibly, in PC12 cells, SRC SH2 displacement can be already efficiently mediated by other means (perhaps involving Sin itself (24)), rendering the contribution of tyrosine-phosphorylated Tyr-798 in RPTPalpha less rate-limiting.

Signaling downstream of SRC, Cas, and Sin is thought to rely on the small GTPase Rap1 (24). Although Crk-mediated Rap1 activation is itself implicated in sustained ERK activation (44), our data argue for a contribution of Crk separate from this role. A worthwhile avenue for further dissection of the mechanism of control of neurite outgrowth by Sin-Crk coupling may involve the contribution of Rac-like small G proteins. The controlling role of Cas-Crk complexes in fibroblast motility has been shown to depend on this pathway (20). DOCK180, recruited by Crk, activates Rac1 (51), which could thus exert localized effects on the actin cytoskeleton. Rac and Cdc42 stimulate filopodia and lamellipodia in the growth cone of neuronal cells, and a balance between Rho-like and other small G protein activities may control neurite outgrowth (52). The viral v-Crk oncogene has been shown to control Rho and to modulate axonal growth in vitro and in vivo (53, 54).

SRC activity and Cas phosphorylation are induced in response to cell-cell contact (55) and membrane depolarization (56). We suggest that neuritogenic signaling by the SRC > Sin-Cas > Crk cassette may be particularly relevant for stimuli that rely heavily on SFKs for promoting neurite outgrowth, such as cell-cell adhesion molecules (8, 9). Indeed, RPTPalpha localizes to areas of cell-cell contact (Fig. 2), and several cell-cell adhesion molecules interact with PTPs in neuronal cells (28, 57); particularly, glycosylphosphatidylinositol-linked contactin associates in cis with RPTPalpha and the SFK Fyn (11). We have thus far not observed clear effects of selected cell-cell adhesion or extracellular matrix molecules or growth factors on the total level of Sin phosphorylation (data not shown); very likely this issue will require a detailed one-by-one analysis of phosphorylation sites in Sin. At any rate, a role for SRC > Sin-Cas > Crk signaling in specifying neurite outgrowth may help solve two paradoxes associated with the concept of sustained ERK activation as necessary and sufficient for neurite outgrowth (1). First, given the complex multiplicity of neural cell types, "process extension" would not be expected to be a unitary event, making reliance on a single pathway unlikely (3, 7). Second, the ability of cells to elaborate multiple processes with different and plastic properties demands control mechanisms that can act locally. A role for SRC, whose localization and activity are tightly regulated, in assembly of localized signaling complexes around scaffolding proteins such as Sin or Cas may be relevant in this respect.

    ACKNOWLEDGEMENTS

We thank M. Chao and I. Lax for comments and A. Bouton, B. Mayer, T. Parsons, E. Skolnik, and D. Unutmaz for reagents.

    FOOTNOTES

* This work was supported by National Institutes of Health Grant CA68365, a grant from the American Heart Association (New York City affiliate), and a Hirschl career scientist award.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The on-line version of this article (available at http://www.jbc.org) contains a supplemental figure.

To whom correspondence should be addressed.: Dept. of Pharmacology, New York University School of Medicine, 550 First Ave., New York, NY 10016. Tel.: 212-263-7120; Fax: 212-263-7133; E-mail: jan.sap@med.nyu.edu.

Published, JBC Papers in Press, February 26, 2002, DOI 10.1074/jbc.M111902200

    ABBREVIATIONS

The abbreviations used are: ERK, extracellular signal-regulated kinase; EGF, epidermal growth factor; FGF, fibroblast growth factor; NGF, nerve growth factor; PTP, protein-tyrosine phosphatase; RPTP, receptor protein tyrosine phosphatase; SFK, SRC family kinase; wt, wild type.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Marshall, C. J. (1995) Cell 80, 179-185[CrossRef][Medline] [Order article via Infotrieve]
2. Peng, X., Greene, L. A., Kaplan, D. R., and Stephens, R. M. (1995) Neuron 15, 395-406[CrossRef][Medline] [Order article via Infotrieve]
3. Vaillancourt, R. R., Heasley, L. E., Zamarripa, J., Storey, B., Valius, M., Kazlauskas, A., and Johnson, G. L. (1995) Mol. Cell. Biol. 15, 3644-3653[Abstract]
4. Alema, S., Casalbore, P., Agostini, E., and Tato, F. (1985) Nature 316, 557-559[CrossRef][Medline] [Order article via Infotrieve]
5. Kremer, N. E., D'Arcangelo, G., Thomas, S. M., DeMarco, M., Brugge, J. S., and Halegoua, S. (1991) J. Cell Biol. 115, 809-819[Abstract/Free Full Text]
6. Rusanescu, G., Qi, H., Thomas, S. M., Brugge, J. S., and Halegoua, S. (1995) Neuron 15, 1415-1425[CrossRef][Medline] [Order article via Infotrieve]
7. Kuo, W. L., Chung, K. C., and Rosner, M. R. (1997) Mol. Cell. Biol. 17, 4633-4643[Abstract]
8. Ignelzi, M. A. j., Miller, D. R., Soriano, P., and Maness, P. (1994) Neuron 12, 873-884[CrossRef][Medline] [Order article via Infotrieve]
9. Beggs, H. E., Soriano, P., and Maness, P. F. (1994) J. Cell Biol. 127, 825-833[Abstract/Free Full Text]
10. Beggs, H. E., Baragona, S. C., Hemperly, J. J., and Maness, P. F. (1997) J. Biol. Chem. 272, 8310-8319[Abstract/Free Full Text]
11. Zeng, L., D'Alessandri, L., Kalousek, M. B., Vaughan, L., and Pallen, C. J. (1999) J. Cell Biol. 147, 707-714[Abstract/Free Full Text]
12. Helmke, S., Lohse, K., Mikule, K., Wood, M. R., and Pfenninger, K. H. (1998) J. Cell Sci. 111, 2465-2475[Abstract]
13. Boyer, B., Roche, S., Denoyelle, M., and Thiery, J. P. (1997) EMBO J. 16, 5904-5913[CrossRef][Medline] [Order article via Infotrieve]
14. Fincham, V. J., and Frame, M. C. (1998) EMBO J. 17, 81-92[CrossRef][Medline] [Order article via Infotrieve]
15. Stofega, M. R., Yu, C. L., Wu, J., and Jove, R. (1997) Cell Growth Differ. 8, 113-119[Abstract]
16. Hakak, Y., and Martin, G. S. (1999) Mol. Cell. Biol. 19, 6953-6962[Abstract/Free Full Text]
17. Aftab, D. T., Kwan, J., and Martin, G. S. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 3028-3033[Abstract/Free Full Text]
18. Oldham, S. M., Cox, A. D., Reynolds, E. R., Sizemore, N. S., Coffey, R. J., Jr., and Der, C. J. (1998) Oncogene 16, 2565-2573[CrossRef][Medline] [Order article via Infotrieve]
19. Cary, L. A., Han, D. C., Polte, T. R., Hanks, S. K., and Guan, J. L. (1998) J. Cell Biol. 140, 211-221[Abstract/Free Full Text]
20. Klemke, R. L., Leng, J., Molander, R., Brooks, P. C., Vuori, K., and Cheresh, D. A. (1998) J. Cell Biol. 140, 961-972[Abstract/Free Full Text]
21. O'Neill, G. M., Fashena, S. J., and Golemis, E. A. (2000) Trends Cell Biol. 10, 111-119[CrossRef][Medline] [Order article via Infotrieve]
22. Honda, H., Oda, H., Nakamoto, T., Honda, Z., Sakai, R., Suzuki, T., Saito, T., Nakamura, K., Nakao, K., Ishikawa, T., Katsuki, M., Yazaki, Y., and Hirai, H. (1998) Nat. Genet. 19, 361-365[CrossRef][Medline] [Order article via Infotrieve]
23. Yano, H., Uchida, H., Iwasaki, T., Mukai, M., Akedo, H., Nakamura, K., Hashimoto, S., and Sabe, H. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 9076-9081[Abstract/Free Full Text]
24. Xing, L., Ge, C., Zeltser, R., Maskevitch, G., Mayer, B. J., and Alexandropoulos, K. (2000) Mol. Cell. Biol. 20, 7363-7377[Abstract/Free Full Text]
25. Schwartzberg, P. L. (1998) Oncogene 17, 1463-1468[CrossRef][Medline] [Order article via Infotrieve]
26. Zheng, X. M., Resnick, R. J., and Shalloway, D. (2000) EMBO J. 19, 964-978[CrossRef][Medline] [Order article via Infotrieve]
27. Burnham, M. R., Bruce-Staskal, P. J., Harte, M. T., Weidow, C. L., Ma, A., Weed, S. A., and Bouton, A. H. (2000) Mol. Cell. Biol. 20, 5865-5878[Abstract/Free Full Text]
28. Petrone, A., and Sap, J. (2000) J. Cell Sci. 113, 2345-2354[Abstract]
29. Harder, K. W., Moller, N. P. H., Peacock, J. W., and Jirik, F. R. (1998) J. Biol. Chem. 273, 31890-31900[Abstract/Free Full Text]
30. Bhandari, V., Lim, K. L., and Pallen, C. J. (1998) J. Biol. Chem. 273, 8691-8698[Abstract/Free Full Text]
31. Zheng, X. M., Wang, Y., and Pallen, C. J. (1992) Nature 359, 336-339[CrossRef][Medline] [Order article via Infotrieve]
32. den Hertog, J., Pals, C. E. G. M., Peppelenbosch, M., Tertoolen, L. G. J., De, Laat, S. W., and Kruijer, W. (1993) EMBO J. 12, 3789-3798[Medline] [Order article via Infotrieve]
33. Ponniah, S., Wang, D. Z., Lim, K. L., and Pallen, C. J. (1999) Curr. Biol. 9, 535-538[CrossRef][Medline] [Order article via Infotrieve]
34. Su, J., Muranjan, M., and Sap, J. (1999) Curr. Biol. 9, 505-511[CrossRef][Medline] [Order article via Infotrieve]
35. den Hertog, J., Tracy, S., and Hunter, T. (1994) EMBO J. 13, 3020-3032[Medline] [Order article via Infotrieve]
36. Su, J., Yang, L.-T., and Sap, J. (1996) J. Biol. Chem. 271, 28026-28096
37. Lammers, R., Lerch, M. M., and Ullrich, A. (2000) J. Biol. Chem. 275, 3391-3396[Abstract/Free Full Text]
38. Alexandropoulos, K., and Baltimore, D. (1996) Genes Dev. 10, 1341-1355[Abstract/